ロード中...
Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
BACKGROUND: Acute rejection remains a major problem in renal transplantation and represents one of the most important causes of chronic allograft dysfunction and late graft loss. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the inter...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Kowsar
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3614279/ https://ncbi.nlm.nih.gov/pubmed/23573470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/numonthly.1806 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|